Dr. Matthew Johnson: Psychedelics for Treating Mental Disorders | Episode 38
Main Takeaways
Psychedelics are a class of compounds that acutely alter the sense of self and reality, with examples including LSD, psilocybin, DMT, and mescaline.
Classic psychedelics increase glutamine transmission downstream and can have persisting changes in self-representation.
Anti-cholinergics lead to true hallucinations, while MDMA is considered an empathogen and is used clinically for trauma.
Psilocybin and LSD target the serotonin system, and the guided psychedelic experience involves preparation, pure psilocybin administration, and emotional release.
Psychedelics are contraindicated for certain predispositions or conditions, and there are dangers involved, such as cases of people dying or getting injured.
Microdosing involves taking a fraction of the entry-level dose and can have potential anti-depressant effects, but the greatest effects come from "heroic" doses.
Psychedelics may have potential for the treatment and reversal of traumatic neurological injury and brain repair.
Federally, all psychedelics are schedule 1 compounds, but there is a state-level legalization effort in Oregon for psilocybin therapy.
There is no formal research yet on the effects of psychedelics on youth, but the FDA has signaled a desire to see studies in this area.
While there may be potential benefits to psychedelic use, caution and regulation are necessary. MDMA may be approved for prescription for PTSD within the next few years.
